The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer’s disease

Marina A. Lynch
Trinity College Institute for Neuroscience,
Trinity College,
Dublin 2,
Ireland.
Email: lynchma@tcd.ie
Tel: 353-1-896-8531
Fax: 353-1-896-3545.

Abstract
Neuroinflammatory changes are a characteristic of several, if not all, neurodegenerative diseases including Alzheimer’s disease (AD) and are typified by increased microglial activation. Microglia express several receptors making them highly reactive and plastic cells, and, at least in vitro, they adopt different phenotypes in a manner analogous to their peripheral counterparts, macrophages. Microglia also express numerous cell surface proteins enabling them to interact with cells and the evidence indicates that maintenance of microglia in a quiescent state relies, at least to some extent, on an interaction with neurons by means of specific ligand-receptor pairs for example CD200-CD200R. It is clear that microglia also interact with T cells and recent evidence indicates that co-incubation of microglia with Th1 cells markedly increase their activation. Under normal conditions, small numbers of activated T cells gain entry to the brain and are involved in immune surveillance but infiltration of significant numbers of T cells occurs in disease and following injury. The consequences of T cell infiltration appear to depend on the conditions, with descriptions of both neurodestructive and neuroprotective effects in animal models of different diseases. This review will discuss the modulatory effect of T cells on microglia and impact of infiltration of T cells into the brain with a focus on AD and will propose that infiltration of interferon (IFN)-γ-producing cells may be an important factor in triggering inflammation that is pathogenic and destructive.

Introduction
Although the pathological hallmarks of Alzheimer’s Disease (AD) were described over a decade ago, the pathogenesis of the late-onset form of the disease remains poorly understood. One theory, the amyloid hypothesis, suggests that the accumulation of β-amyloid (Aβ), because of a decrease in Aβ clearance, perhaps accompanied by increased
processing of amyloid precursor protein (APP), triggers a cascade of damaging reactions. Another theory proposes that tau hyperphosphorylation is key to the demise of neurons. However the trigger leading to the initial changes has not been identified, and the likelihood is that there is not a single factor but a collection of coincident events which superimpose upon already-existing age-related changes. For some time now it has been recognized that inflammatory changes may be a factor in accelerating disease onset. Indeed many of the risk factors for the disease, for example atherosclerosis, neurotrauma, Type 1 diabetes and infection, are associated with inflammatory changes.

**Neuroinflammation and AD**

A great deal of evidence indicates that inflammatory changes are a feature of AD and it is agreed that a key change is an increase in microglial activation which was originally described by Alzheimer over 100 years ago. Several reports have confirmed this observation and have shown that activated cells cluster around Aβ-containing plaques. An increase in expression of inflammatory cytokines, interleukin (IL)-1β, IL-6 and tumour necrosis factor (TNF)α has been observed in the AD brain and IL-1-positive microglia co-localize with Aβ-containing plaques, as do activated astrocytes. These changes are associated with other indicators of inflammatory changes including increased expression of several chemokines and elements of the complement activation pathway. However it is still debated whether these changes are a consequence of the disease or contribute to its pathogenesis; this is a difficult issue to dissect since the evidence from model systems indicates the existence of a cycle in which inflammatory changes drive Aβ accumulation while Aβ stimulates glia to produce inflammatory mediators. A possible resolution to this question was presented when early epidemiological evidence indicated that the incidence or severity of AD was reduced in individuals who were treated with non-steroidal anti-inflammatory drugs (NSAID). These observations suggested that anti-inflammatory agents might be a useful therapeutic option for the treatment of the disease, but several clinical trials have failed to identify a beneficial effect of anti-inflammatory agents. It has been argued that, since inflammatory changes occur early in the disease, only very early intervention with anti-inflammatory treatments is likely to be valuable and indeed in a study where participants were ≥ 65 years on enrollment (older than participants in other studies), the use of NSAIDs was detrimental with adjusted hazard ratio of risk for AD of 1.57. Interestingly, postmortem examination of brain tissue from non-demented elderly individuals indicated a correlative decrease in microglial activation and senile plaque number in those treated with NSAIDs but not steroids, although other data have not shown this.

**Microglia and macrophages share certain properties**

Microglia are the primary immune cells in the brain and they are often referred to as macrophages of the brain, although we now know that microglia are an ontogenically distinct population of cells derived from primitive haematopoetic cells in the yolk sac. Therefore microglia, being confined to the brain, are protected by the blood brain barrier (BBB), from exposure to circulating high molecular weight molecules as well as the vast array of stimuli encountered by macrophages. Morphologically, microglia and macrophages are somewhat distinct. Under resting conditions microglia, unlike macrophages, are multi-processed cells and the processes are constantly motile enabling the cells to sample their microenvironment and react, when necessary, to noxious stimuli. Activation of microglia results in retraction of processes and the cells adopt an amoeboid

This article is protected by copyright. All rights reserved.
morphology. However the cells share many functions and both are phagocytic and function as antigen presenting cells (APC).

Microglia are highly reactive cells and, like macrophages, express a multitude of cell surface receptors \(^{17}\) including pathogen recognition receptors (PPRs), complement receptor, Fc receptors, chemokine and cytokine receptors, and receptors for numerous neurotransmitters \(^{17, 18}\). While macrophages are regularly exposed to pathogen-associated molecular patterns (PAMPs), whereas brain infections are relatively rare and therefore activation of PPRs on microglia is more likely to be induced by damage-associated molecular patterns (DAMPs); these endogenously-generated molecules include ATP and high mobility group box-1 (HMGB-1), that are released from damaged/dying cells \(^{19}\). However an association between AD and certain pathogens has been identified \(^{20}\) and infections can accelerate cognitive decline in AD patients \(^{21, 22}\). Evidence has indicated that a significant proportion of AD brains were positive for *Chlamydia pneumonia* \(^{23}\) while intranasal inoculation of mice with *C. pneumoniae* induced deposition of fibrillar A\(\beta\) associated with reactive glia \(^{24}\). Peripheral challenge with the TLR agonists, LPS or polyriboinosinic-polyribocytidilic acid (PolyI:C), induced amyloid pathology in some \(^{25, 26}\), but not all \(^{27}\), animal models of AD. Herpes simplex virus DNA has also been found in the cortex of a high proportion of individuals with AD \(^{28}\) and the risk of developing AD is exacerbated by the virus in individuals with the type 4 allele of the apolipoprotein E \(^{29}\).

**Several factors act to downregulate microglial activation**

Under resting conditions, microglia are maintained in a relatively quiescent state and, while the evidence suggests that cell-cell interactions are primarily responsible for this, it is also known that some neurotransmitters particularly noradrenaline and acetylcholine also modulate the activation of microglia \(^{30}\). Other factors which assist in maintaining the ‘resting’ state of microglia are the low numbers of T cells in the brain and therefore the minimal expression of potent activators like interferon (IFN)\(\gamma\), the presence of electrically active neurons which suppress glial expression of MHC and co-stimulatory molecules \(^{31}\) and the production by neurons and astrocytes of TGF\(\beta\) and IL-10 \(^{32, 33}\).

Microglia physically interact with other cells and, in the case of microglia-neuron interactions, several ligand-receptor pairs have been shown to support this interaction. Perhaps the 2 best studied pairs are CD200-CD200R and CX3CL1-CX3CR1. CD200 is expressed on many cell types including neurons whereas CD200 receptor expression is confined to cells of the myeloid lineage \(^{34, 35}\); consequently co-culturing microglia with neurons decreases lipopolysaccharide (LPS)- or amyloid-\(\beta\) (A\(\beta\))-induced microglial activation in a CD200-dependent manner \(^{36, 37}\). CD200 deficiency increases inflammatory changes in models of multiple sclerosis \(^{38}\), Parkinson’s Disease \(^{39}\) and experimental autoimmune uveoretinitis \(^{40}\) and these mice also exhibit exaggerated responses to inflammatory challenges \(^{37, 41}\). Perhaps predictably, a fusion protein CD200Fc, which acts on CD200R to induce its signalling, attenuates the inflammatory changes associated with age and A\(\beta\) treatment \(^{42, 43}\) and to decrease the symptoms and inflammatory changes in experimental autoimmune encephalomyelitis \(^{44}\) and collagen-induced arthritis \(^{45, 46}\). Interestingly CD200 is decreased in tissue from individuals with AD \(^{47}\) and in tissue adjacent to the plaques in multiple sclerosis \(^{48, 49}\) and CD200R signalling is dysfunctional in macrophages from individuals with Parkinson’s disease \(^{50}\).
The largely complementary expression of CX3CL1 on neurons and its receptor on microglia suggests an interaction similar to that described for CD200-CD200R, and evidence to support this has been reported. Several studies have reported that disruption in CX3CL1-CX3CR1 interaction is associated with microglial activation and increased secretion of inflammatory cytokines. However in the APP/PS1 transgenic mouse model of AD, knockdown of CX3CR1 was associated with increased clearance of Aβ indicating that the impact of CX3CR1 activation is complex with respect to microglial activation. Interestingly, expression of both ligand and receptor is decreased in hippocampal and cortical tissue in AD.

Other ligand-receptor pairs include CD45 and signal regulatory protein (SIRP)1α which are expressed predominantly on microglia and interact with neuronally-expressed CD22 and CD47 respectively. These interactions function as ‘off’ signals, whose role is to keep microglia in a resting state; other ‘off’ signals include secreted CD22 and fractalkine, secreted neurotrophins and anti-inflammatory cytokines such as IL-10 and IL-4, and several of these factors attenuate IFNγ-, LPS- and Aβ-induced microglial activation.

Astrocytes, like neurons, express CD200 and they also have the ability to interact with microglia to downregulate their activation. Indeed incubation of microglia with CD200-bearing astrocytic membrane preparations attenuate the LPS-induced increase in mRNA expression of IL-1β, TNFα and IL-6 and the LPS-induced increase in release of TNFα and IL-6. However soluble factors secreted by astrocytes also modulate microglial activation and it has been shown that conditioned medium obtained from astrocytes decreased hydrogen peroxide (H2O2)-induced reactive oxygen species (ROS) production, increased expression and activity of the antioxidant enzyme, haemoxgenase-1, and decreased IFNγ-induced inducible nitrous oxide synthase (iNOS) expression in microglia. The modulatory effect of astrocytes on microglial activation perhaps derives from the fact that astrocytes are GABA-ergic cells which impact on GABA receptors expressed by microglia. However it is clear that astrocytes can also release factors which trigger microglial activation and therefore contribute to the changes that occur as a consequence of chronic inflammation.

T cells can also interact with microglia to modulate their function (Table 1). It was shown in co-culture experiments that Th1 cells upregulated expression of markers which are typical of APC in microglia, including MHCII and CD40 induced, whereas Th2 cells were unable to do so. Conversely, microglia induced Th1 cells to release IFNγ but were unable to trigger release of IL-4 from Th2 cells. In addition, conditioned medium obtained from Th1 cells, but not Th2 cells, increased expression of CD80, CD86, CD40 and the adhesion molecule CD54 on microglia; these changes were mimicked by IFNγ and inhibited by anti-IFNγ antibody, although only partially, prompting the authors to conclude that the effect of Th1 cells cannot be attributed exclusively to IFNγ release. We have also reported that T cells, specifically Th1 and Th17 cells, interact with microglia and induce their activation in vitro. Aβ-specific Th1 cells increased production of inflammatory cytokines IL-1β, IL-6 and TNFα and increased expression of MHCII and CD86 on microglia. Th17 cells exerted similar effects, whereas Th2 cells exerted little effect. However Th2 cells attenuated the effect of Th17 cells on microglia but did not inhibit the effect of Th1 cells. MOG-specific Th1 cells and Th1/Th17 cells also increased microglial production of inflammatory cytokines and expression of MHCII, CD80 and CD86. Consistent with these findings, it has also been shown that co-culture of organotypic slices with OVA-specific or myelin basic protein-specific Th1 cells increased...
microglial activation whereas Th2 cells exerted no effect. These in vitro data all suggest that APC function of microglia is increased when cells interact with Th1 and Th17 cells and interestingly upregulation of APC function induced by Th1 cells appears to be associated with a switch in microglial phenotype away from one that is efficient at phagocytosis. The evidence from our recent studies suggest that the modulatory effect of T cells on microglial function observed in vitro also occurs in vivo. Focussing on analysis of the effects in an amyloid-overexpressing model of AD, we found that intravenous administration of Aβ-specific Th1 cells into APP/PS1 mice, which tracked to the brain, increased microglial activation and enhanced Aβ pathology and this effect was attenuated in APP/PS1 mice treated with an anti-IFNγ antibody. The effect of Th17 cell administration was less profound whereas injection of Th2 cells was essentially without effect in these mice. The lack of effect of Th2 cells is at variance with an earlier report which suggested a beneficial effect of transfer of Aβ-specific Th2 cells on behavioural deficits and pathology in APP/PS1 mice. This group also reported that Th2 cells reduced the numbers of activated microglia surrounding Aβ-containing plaques.

Do microglia adopt the M1 and M2 phenotypes observed in macrophages?

It has been known for a few decades that macrophages adopt different activation states, identified by upregulation of specific markers, in response to different signals. These are broadly described as M1, an inflammatory phenotype and M2, an anti-inflammatory phenotype. The Th1 cell-derived cytokine IFNγ induces classical activation (M1), and this phenotype is identified by upregulation of TNFα and iNOS. The term alternative activation (M2a phenotype) was first used to describe a macrophage which adopted a phenotype distinct from that induced by IFNγ and LPS. These cells were not capable of producing NO and so were not cytotoxic and, although MHCII expression was increased, the cells were not efficient APC and prevented proliferation of T cells. This phenotype is induced by the Th2 cell-derived cytokines, IL-4, IL-5 and IL-13 and is identified by upregulation of mRNA expression of arginase I, mannose receptor, chitinase 3-like 3 and found in inflammatory zone-1 (FIZZ1). Because the cells were shown to inhibit inflammatory cytokine production, they were recognized as regulatory macrophages. Acquired deactivation (M2c phenotype) is induced by the immunosuppressive cytokines, IL-10 and TGFβ, which are derived from regulatory T cells, and this phenotype is associated with upregulation of anti-inflammatory cytokines like IL-10 and TGFβ and downregulation of factors that contribute to APC function like MHCII. Like macrophages, microglia respond to IL-10 and administration of IL-10 to aged rats decreases microglial activation and neuroinflammatory changes suggesting that microglia can also adopt the acquired deactivated state. It has been shown that this state, which is characterized by an increase in receptors like scavenger receptors, which support their phagocytic function, can also be induced by phagocytosis of apoptotic cells, or TGFβ although the data is largely derived from in vitro studies.

In the past 5 years or so, significant interest has developed in determining whether microglia react to the different stimuli in the same way as macrophages. Although there are data which support this, it remains to be established whether the characteristics of these activation states, and their patterns of stimulation, faithfully translate from the in vitro into the in vivo situation. It is also not entirely clear that the phenotypic markers which apply to macrophages are relevant in the context of microglia. A further issue relates to the nature of the stimuli which trigger classical and alternative activation states since resident
cells in the brain produce limited IFNγ and IL-4. It must therefore be considered that infiltrating cells are responsible for production of these cytokines and consequently for triggering polarization of microglia into classically- and alternatively-activated phenotypes, or that other polarizing stimuli substitute in the brain. Despite these caveats, it is known that IFNγ potently activates microglia and among the changes observed is increased expression of TNFα and iNOS as well as upregulation of other inflammatory cytokines and markers typical of an APC in vivo \[^{82, 83}\] as well as in vitro \[^{84}\]. A recent very comprehensive study in microglia also identified that COX2 mRNA was markedly increased in IFNγ-treated cells while mannose receptor and arginase-1 mRNA were upregulated by IL-4 \[^{85}\]. Alternatively-activated macrophages have a key role in tissue repair and restructuring of the extracellular matrix \[^{81}\]; whereas alternatively-activated microglia may also play a role in tissue repair, a key role is likely to be re-establishing homeostasis following an inflammatory stimulus.

Identifying factors that enable switching of microglia from an inflammatory to an anti-inflammatory phenotype is an important goal since it is likely to point towards strategies that might prevent chronic inflammation. One potential molecular switch is activation of PPARγ \[^{86}\]; its activation by pioglitazone increased expression of several markers of alternative activation in 12 month-old APP/PS1 mice. This was associated with decreased Aβ pathology suggesting that alternatively-activated microglia are more phagocytic \[^{87}\]. Inhibition of NADPH oxidase or functional deletion of p47phox have also been identified as factors which potentially control the polarization of microglia from the classically- to the alternatively-activated state in the brain \[^{88}\]. Similarly, knockdown of NLRP3 in APP/PS1 mice switches microglia from the classical to the alternative activation state \[^{89}\]. The tetrapeptide, (threonine-lysine-proline-arginine), tuftsin, also induces an anti-inflammatory phenotype in vitro and in vivo \[^{90}\] whereas CD45 which inhibits the interaction between CD40 ligand and receptor appears to switch off the inflammatory M1 state in vivo \[^{91}\]. In contrast, age induces microglia to adopt an inflammatory phenotype \[^{92}\]. Recent evidence has revealed that specific microRNAs may be key factors in polarization of microglia, and it has been suggested that miR-155 skews microglia towards an M1 phenotype, at least in cultured cells \[^{93}\]. However changes in upregulation of other miRNAs including miR-101 and miR-125b, together with downregulation of miR-92, also appear to be characteristics of the M1 phenotype \[^{94}\].

**What microglial phenotype is observed in AD and is this linked with Aβ accumulation?**

With the focus on the amyloid hypothesis of AD, the question of which microglial phenotype is associated with Aβ accumulation and/or with greater phagocytic capability has been the subject of intense interest. In the context of AD in particular, it is important to unravel the factors that contribute to the apparent inability of microglia to phagocytose Aβ despite the proximity of activated cells to the Aβ-containing plaques. The consensus suggests that an inflammatory milieu inhibits the phagocytic function of microglia. Thus it has been reported that Th1 cytokines inhibit microglial phagocytosis of Aβ, whereas IL-4 and IL-10 have the opposite effect \[^{73}\]. Jimenez and colleagues demonstrated that the microglial phenotype changed with age in APP/PS1 mice, shifting from an alternative activation state which was associated with phagocytic capability to a classically-activated phenotype which was associated with proinflammatory cytokine production. Aβ-immunoreactivity was observed in tomato lectin-stained microglia that surrounded plaques.
This article is protected by copyright. All rights reserved.

in 6 month-old APP/PS1 mice and the evidence indicated that these cells were alternatively-activated microglia because they stained positively for YM-1. By 18 months of age, microglia had adopted a classically-activated phenotype and these cells appeared not to be phagocytic. It was also shown that knocking out IFNγR1 in APP mice was associated with reduced Aβ deposition in cortex and hippocampus and this correlated with decreased gliosis. Additionally, alternative activation of microglia in APP/PS1 mice, which was induced by the PPARγ activator pioglitazone or NLRP3 knockdown was associated with an increase in Aβ clearance. We have found that adoptive transfer of Aβ-specific Th1 cells markedly increased microglial activation, inflammatory changes and Aβ pathology but Th2 cells were without effect. This contrasts with the findings of others which suggested that injection of Th2 cells decreased plaque burden. This finding followed up a previous report from this group which demonstrated that injection of a mixed population of Aβ-specific T cells decreased Aβ pathology in 8.5 month-old APP/PS1 mice though this effect was not evident if an enriched Th1 preparation was injected. Our evidence has indicated that, even in 6-7 month-old APP/PS1 mice, there was evidence of an inflammatory phenotype, and in a recent study we were unable to detect any evidence of alternatively-activated microglia in 12 month-old APP/PS1 mice (Minogue et al. unpublished). This may vary between models of AD since increased mRNA expression of TNFα (although not iNOS), as well as mannose receptor and arginase-1, was observed in cortical tissue prepared from 60 week-old Tg2576 mice suggesting a heterogeneity in microglial phenotypes in at least this model of AD. This heterogeneity was also observed in transgenic mice that overexpressed APP only but was more marked in APP mice with a deficiency in NOS2. However this group have suggested that amyloid deposition is greater in circumstances in which there is upregulation of markers of alternatively-activated microglia which is at variance with most of the literature.

It has been suggested that macrophages rather than microglia are the primary phagocytes in the brain and that these infiltrating cells are key to reparative processes. However the evidence suggests that alternatively-activated macrophages, like microglia, have enhanced phagocytic capability and the possibility exists that the inflammatory microenvironment in the AD brain, which inhibits efficient phagocytosis, prevents the macrophages from adopting the alternatively-activated state. This may explain the finding that macrophages which infiltrate the brain in AD patients fail to phagocytose Aβ efficiently. Therefore, a therapeutic value of anti-inflammatory therapies given at the appropriate time in the disease, may be a reduction on Aβ pathology.

**Does infiltration of peripheral cells contribute to the onset or progression of AD?**

In AD and amyloid-based transgenic models of AD, microglia adopt an inflammatory phenotype, and increased expression TNFα and iNOS, which are markers of classical activation, have been reported in the brain of mouse models of AD and in postmortem tissue tissue from AD patients. A link between microglial activation and tau hyperphosphorylation has also been reported, though accumulating tau in a mouse model in which tau is overexpressed, leads to an LPS-induced upregulation of markers of alternative activation. If it is accepted that IFNγ is required for inducing classical activation of microglia, then it follows that there must be infiltration of IFNγ-producing cells, for example Th1 cells, since IFNγ is generally not produced to any significant degree by resident cells in the brain. However it must be considered that factors other than IFNγ...
can induce changes that mimic classical activation and, in this context it is known that several of the changes induced by IFNγR activation including upregulation of TNFα and iNOS, as well as cell surface markers of activation like MHCII and CD40, are also triggered by Aβ TLR agonists. 42,108

It is widely accepted that T cell entry into the CNS under normal circumstances is very limited and the evidence suggests that their role is immunosurveillance 109,110; it has been proposed that cells gain entry at the choroid plexus under these conditions when there is no evidence of neuroinflammation 111. However significant infiltration of immune cells occurs in neuroinflammatory conditions 111. The role of these cells in the pathogenesis of multiple sclerosis is well rehearsed 112,113, but a recent study revealed that T cell infiltration also occurs in Parkinson’s disease 114 and the evidence from animal studies suggests that the presence in the brain of CD4+ cells significantly contributes to the demise of dopaminergic cells.

The first evidence that T cells were present in the brain of AD patients was presented 25 years ago 115, 116 and similar findings have been sporadically reported since 12,117-122. These cells were found to be in close apposition with plaques and activated glia 119. CD8+ cells have been found in the post-mortem brain of individuals with mild-moderate AD but also in non-demented controls, though some evidence suggests that their numbers were decreased in AD brains 12,121. We have recently shown that there is significant infiltration of T cells, particularly IFNγ-positive and IL-17-positive T cells, into the brain of 6-8 month-old APP/PS1 mice 74 and this infiltration increases with age so that infiltration in 12 month-old animals was significantly greater (McManus et al., unpublished). T cell infiltration has also been shown in 18 month-old, but not 6 month-old, APP/PS1 mice 92.

Infiltration of immune cells may result from the creation of a chemotactic gradient as a consequence of increased expression of chemokines in brain; CCL3, CXCL10 and CCL5 have established lymphocyte chemotactic properties 123-125 and increased expression of these chemokines has been reported in AD 126-128. Interestingly, expression of CCR5 and CXCR3 on T cells obtained from AD patients has been reported 129-131. A loss of BBB integrity, which will also enable cell infiltration, has been described in AD; increased fibrinogen immunoreactivity, altered immunohistochemical staining for von Willebrand’s factor, and dystrophic vessels have been reported 132. This was accompanied by marked glial activation; activated microglia were co-located with fibrinogen immunoreactivity, suggesting that fibrinogen induce cell activation 133. Interestingly intrahippocampal injection of Aβ induced BBB permeability in the rat hippocampus, as revealed by fibrinogen immunoreactivity, whereas we have recently found that the age-related accumulation of endogenous Aβ in APP/PS1 mice was accompanied by increased BBB permeability, infiltration of CD4+IFNγ+ cells and increased expression of markers of classical activation of microglia. (Minogue et al., unpublished).

Summary

A proposed sequence of events presented in Figure 1 suggests that BBB permeability, which is increased in AD, together with the creation of a chemotactic gradient, leads to infiltration of IFNγ-producing T cells. Inflammatory T cells together with IFNγ, produced by these cells, induces classical activation of microglia which leads to inflammatory cytokine and chemokine production. These changes act to increase APP processing and Aβ accumulation and also induce BBB permeability with further infiltration of cells, and
so a cycle of damaging events ensues. It is proposed that interrupting this cycle is key to limiting disease progression in AD. Validation (or otherwise) of this hypothesis requires significant investigation. For example, it predicts that preventing BBB permeability or infiltration of IFNγ-producing T cells will reduce inflammation and pathology. It also predicts that IFNγ-induced changes in microglia, and upregulation of chemokines, induce further BBB permeability whereas the effects of microglia which have an anti-inflammatory phenotype are not. It remains to be established whether these changes impact in the predicted way on neuronal and cognitive function.

REFERENCES


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.


Table 1. Effect of T cells on microglial activation

<table>
<thead>
<tr>
<th>Main finding</th>
<th>Preparation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>OVA-specific Th1 cells increased expression of MHCII, CD40 and CD54 on microglia. Th2 cells had little effect.</td>
<td>Microglia from BALB/c mice. T cells prepared from transgenic mice carrying a TCR DO11.10 for cOVA\textsubscript{323–339} peptide mouse.</td>
<td>68</td>
</tr>
<tr>
<td>Conditioned medium from Th1 cells increased expression of CD80, CD86, CD40 and CD54 and release of TNF\textalpha, IL-6 and CXCL10. Medium from Th2 cells had no significant effect.</td>
<td>Microglia from human tissue obtained following surgery. T cells from healthy volunteers.</td>
<td>69</td>
</tr>
<tr>
<td>Aβ-specific Th1 cells increased expression of MHCII and CD86 and release of IL-1β, TNF\textalpha and IL-6. Aβ-specific Th17 cells exerted a similar effect. Th2 cells had little effect</td>
<td>Mixed glia and T cells from C57BL/6 mouse.</td>
<td>70</td>
</tr>
<tr>
<td>MOG-specific Th1 cells increased expression of MHCII, CD80, CD86 and CD40 and release of IL-1β, TNF\textalpha. MOG-specific Th1/Th17 cells exerted a similar effect.</td>
<td>Mixed glia and T cells from C57BL/6 mouse.</td>
<td>71</td>
</tr>
<tr>
<td>MBP-specific and OVA-specific Th1 cells increased CD80 expression (with or without cell contact) but decreased CD86 expression (slices already expressed CD86).</td>
<td>Organotypic entorhinal-hippocampal slice cultures prepared from 11 day-old mice. Th1 and Th2 cell lines from transgenic mice carrying a T-cells receptor (TCR) for MBP peptide Ac1-11 or transgenic mice carrying a TCR DO11.10 for cOVA\textsubscript{323–339} peptide.</td>
<td>72</td>
</tr>
<tr>
<td>Adoptive transfer of Aβ-specific Th1 cells increased CD11b immunoreactivity and Aβ accumulation in APP/PS1 transgenic mice. Th2 cells had little effect.</td>
<td>T cells from C57BL/6 mice adoptively transferred into APP/PS1 mice.</td>
<td>74</td>
</tr>
<tr>
<td>Adoptive transfer of Aβ-specific Th2 cells decreased plaque-associated microglial numbers</td>
<td>Th2 cells from congenic mice adoptively transferred into APP/PS1 mice.</td>
<td>75</td>
</tr>
<tr>
<td>T cell infusion reduced area covered by microglia surrounding Aβ deposits. Th1 cell-enriched infusion was less effective.</td>
<td>T cell- enriched infusate prepared from Tg2576 mice. Adoptively transferred into 8.5 month-old Tg2576 mice.</td>
<td>96</td>
</tr>
</tbody>
</table>